

## **SCHEDULE 13 – NEW DRUG FUNDING PROGRAM**

### **PART A – PROGRAM DESCRIPTION**

Cancer Care Ontario (CCO) administers the following three cancer drug reimbursement programs on behalf of the Ministry of Health (MOH):

- The New Drug Funding Program (NDFP) funds hospital-administered injectable cancer drugs.
- The Evidence-Building Program (EBP) provides funding for cancer drugs where the evidence is emerging or evolving, and where additional real-world data is collected as a part of reimbursement process to confirm clinical and cost-effectiveness and inform a final funding decision.
- The Case-by-Case Review Program (CBCRP) considers individual patient funding requests for both oral and injectable cancer drugs in immediately life-threatening circumstances where regular funding is not expected via other funding mechanisms. The program adjudicates requests and reimburses the costs of hospital-administered drugs approved for funding whereas the Drugs and Devices Division of the MOH reimburses the cost of community-based drugs approved for funding.

The Provincial Drugs Reimbursement Programs (PDRP) unit of CCO is operationally responsible for administering these three reimbursement programs consistent with the policy intent and funding provided by the Ministry, through the Executive Officer of the Ontario Public Drug Programs.

**PART B – FINANCIAL/PERFORMANCE AND REPORTING OBLIGATIONS**

Dedicated Funding Envelopes	Funding Branch/Division	TP Parent/Cost Centre
NDFP Operations – DFE1	Drug Programs Policy and Strategy Branch Drugs and Devices Division	Vote 1405/02 Cost Center: 530407

	Activities	2018-19 Opening	2018-19 Incremental Base	2018-19 One-Time	2018-19 Total Allocation	2019-20 Opening Base	2019/20 Administrative Efficiency	2019-20 Incremental Base	2019-20 One-Time	2019-20 Total Allocation	Deliverables
		A	B	C	D=A+B+C	E=A+B	F	G	H	I= E+F+G+H	
DFE 1	NDFP Operations	\$378,839,000	\$36,900,000	\$42,200,000	\$457,939,000	\$415,739,000	(\$151,603)	\$21,000,000*	\$83,084,000	\$519,671,397	<ol style="list-style-type: none"> <li>1. Implement MOH funding recommendations for NDFP and EBP (develop enrolment forms and FAQ documents and communicate criteria to RCCs and Hospitals)</li> <li>2. Adjudicate electronic enrolment forms and treatment claims submitted by RCCs and hospitals to determine eligibility criteria of cancer patients under the NDFP and EBP</li> <li>3. Work with the MOH to understand new drug submissions through the completion of survey and meetings with manufacturers</li> <li>4. Develop evaluation processes for cancer drugs and companion tests, at the request of the MOH</li> <li>5. Track drug utilization and trends, forecast drug expenditures and monitor drug prices and shortages</li> </ol>

											6. Provide feedback on drug reviews in collaboration with the MOH, CCO's DACs, pCODR, and pCPA 7. Act as the secretariat to the Ontario Steering Committee for Cancer Drugs 8. Work with MOH, the Pediatric Oncology Group of Ontario (POGO) and the specialized pediatric cancer centres/tertiary hospital sites to: <ul style="list-style-type: none"> <li>- fund and support the delivery of the Asparaginase drugs used in the treatment of children with Acute Lymphoblastic Leukemia (ALL)</li> <li>- identify opportunities for managing funding of pediatric drugs</li> <li>-</li> </ul>
	<b>Fiscal Grand Total</b>	<b>\$378,839,000</b>	<b>\$36,900,000</b>	<b>\$42,200,000</b>	<b>\$457,939,000</b>	<b>\$415,739,000</b>	<b>(\$151,603)</b>	<b>\$21,000,000</b>	<b>\$83,084,000</b>	<b>\$519,671,397</b>	
	<b>Grand Total Rounded</b>	<b>\$378,839,000</b>	<b>\$36,900,000</b>	<b>\$42,200,000</b>	<b>\$457,939,000</b>	<b>\$415,739,000</b>	<b>(\$151,600)</b>	<b>\$21,000,000</b>	<b>\$83,084,000</b>	<b>\$519,671,400</b>	

\*The incremental base of \$21.0M is the approved increase in FY2019-20 as per 2018-19 PRRT

## PART C – REPORTING

Within ninety (90) days of the end of each Quarter, CCO shall provide the MOH with a Quarterly report on drug-criteria specific utilization. The report shall list each Approved Cancer Drug and its related clinical criteria. The utilization data shall include the number of new cases, number of treated cases, number of treatments, and the total cost of the treatments.

Disease Site Group	Drug	Eligibility Criteria	New Case	Treated Case	Total Treatments
CBCRP Claims					
Outstanding claims - Reversible discrepancies					
Administrative Costs					
<b>Progress Report:</b>					
<b>Deliverables:</b>					

## PART D – PAYMENT SCHEDULE

The MOH will provide two payments per month to CCO, each being 1/24 of the annualized approved budget. To reduce recoveries in the year end reconciliation, reductions to Q4 payments may be made in-year if the Q3 report forecasts a surplus.